Hayek Kallen Investment Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.88M Sell
37,538
-532
-1% -$79.8K 1.78% 17
2026
Q1
$5.82M Buy
+38,070
New +$5.84M 1.89% 16
2025
Q4
Sell
-38,865
Closed -$4.98M 150
2025
Q3
$4.98M Sell
38,865
-25
-0.1% -$3.05K 1.57% 19
2025
Q2
$4.71M Sell
38,890
-595
-2% -$67.1K 1.6% 19
2025
Q1
$4.4M Sell
39,485
-590
-1% -$62.8K 1.62% 19
2024
Q4
$3.9M Sell
40,075
-245
-0.6% -$26.1K 1.42% 23
2024
Q3
$4.64M Sell
40,320
-375
-0.9% -$42.5K 1.64% 19
2024
Q2
$4.33M Sell
40,695
-270
-0.7% -$27.1K 1.62% 18
2024
Q1
$3.96M Buy
40,965
+180
+0.4% +$18.5K 1.52% 22
2023
Q4
$4.12M Sell
40,785
-136
-0.3% -$13.1K 1.72% 19
2023
Q3
$4.17M Sell
40,921
-86
-0.2% -$8.73K 1.87% 16
2023
Q2
$4.14M Buy
41,007
+1,819
+5% +$182K 1.76% 18
2023
Q1
$3.6M Sell
39,188
-1,157
-3% -$101K 1.63% 21
2022
Q4
$3.66M Sell
40,345
-600
-1% -$50.5K 1.69% 20
2022
Q3
$3.11M Sell
40,945
-100
-0.2% -$8.29K 1.46% 23
2022
Q2
$3.47M Sell
41,045
-900
-2% -$79K 1.51% 24
2022
Q1
$3.68M Sell
41,945
-875
-2% -$75.8K 1.36% 28
2021
Q4
$3.75M Sell
42,820
-115
-0.3% -$9.55K 1.34% 29
2021
Q3
$3.51M Sell
42,935
-388
-0.9% -$34.9K 1.6% 24
2021
Q2
$3.95M Buy
43,323
+124
+0.3% +$11K 1.66% 22
2021
Q1
$3.69M Buy
43,199
+26
+0.1% +$2.33K 1.66% 23
2020
Q4
$4.08M Sell
43,173
-28
-0.1% -$2.45K 1.97% 18
2020
Q3
$3.76M Sell
43,201
-220
-0.5% -$19.1K 2.1% 14
2020
Q2
$3.79M Sell
43,421
-388
-0.9% -$33.5K 2.15% 14
2020
Q1
$3.61M Sell
43,809
-879
-2% -$78.4K 2.42% 12
2019
Q4
$4.23M Sell
44,688
-160
-0.4% -$14.4K 2.44% 13
2019
Q3
$3.9M Sell
44,848
-592
-1% -$53.2K 2.43% 13
2019
Q2
$4.15M Sell
45,440
-5,690
-11% -$482K 2.63% 13
2019
Q1
$4.41M Sell
51,130
-1,541
-3% -$124K 2.86% 11
2018
Q4
$4.05M Sell
52,671
-686
-1% -$53.4K 2.9% 11
2018
Q3
$4.12M Hold
53,357
2.64% 13
2018
Q2
$3.61M Sell
53,357
-919
-2% -$63.4K 2.5% 13
2018
Q1
$3.93M Sell
54,276
-1,930
-3% -$147K 2.73% 11
2017
Q4
$4.23M Sell
56,206
-586
-1% -$44.2K 2.77% 11
2017
Q3
$4.37M Sell
56,792
-385
-0.7% -$29.1K 2.99% 11
2017
Q2
$4.28M Sell
57,177
-578
-1% -$41K 2.89% 12
2017
Q1
$3.84M Buy
57,755
+597
+1% +$39.8K 2.66% 13
2016
Q4
$3.73M Buy
57,158
+351
+0.6% +$22.8K 2.72% 13
2016
Q3
$4.02M Buy
56,807
+1,077
+2% +$78.5K 2.87% 14
2016
Q2
$4.12M Buy
55,730
+759
+1% +$52.4K 2.96% 14
2016
Q1
$3.57M Buy
54,971
+140
+0.3% +$9.52K 2.64% 18
2015
Q4
$4.23M Sell
54,831
-1,245
-2% -$98.9K 3.24% 11
2015
Q3
$4.62M Sell
56,076
-2,818
-5% -$251K 3.59% 6
2015
Q2
$5.19M Sell
58,894
-343
-0.6% -$31.5K 3.88% 6
2015
Q1
$5.23M Sell
59,237
-1,725
-3% -$153K 3.86% 5
2014
Q4
$5.06M Sell
60,962
-1,494
-2% -$124K 3.74% 5
2014
Q3
$5.27M Sell
62,456
-3,385
-5% -$274K 4.01% 5
2014
Q2
$5.34M Sell
65,841
-1,540
-2% -$121K 4.04% 5
2014
Q1
$5.13M Sell
67,381
-1,757
-3% -$128K 4.09% 7
2013
Q4
$4.98M Sell
69,138
-1,630
-2% -$113K 3.88% 5
2013
Q3
$4.86M Sell
70,768
-3,722
-5% -$246K 4.02% 4
2013
Q2
$4.72M Buy
+74,490
New +$4.85M 3.99% 5

Other funds holding NVS

Hayek Kallen Investment Management's NVS Position: Q2 2026 in Review

Hayek Kallen Investment Management reduced its Novartis (NVS) stake by 1.4% in Q2 2026, selling an estimated $79.8K and leaving 37,538 shares worth $5.88M. The position accounts for 1.78% of the portfolio, ranked #17.

Hayek Kallen Investment Management first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Hayek Kallen Investment Management held 37,538 shares of Novartis worth $5.88M as of Q2 2026.
  • Hayek Kallen Investment Management sold 532 Novartis shares in Q2 2026, an estimated $79.8K.
  • Novartis made up 1.78% of Hayek Kallen Investment Management's portfolio in Q2 2026, its #17 holding.
  • Hayek Kallen Investment Management first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Hayek Kallen Investment Management's 13F filing for Q2 2026, filed 17 Aug 2026.